FDA Approval Sought for Lurbinectedin in Small Cell Lung Cancer
A new drug application has been submitted to the FDA seeking an accelerated approval for lurbinectedin for use as a second-line treatment for patients with small cell lung cancer.
Related Articles
FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer
SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.
Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma
The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.
Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL
Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC
The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.
FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC
Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.
Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma
The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.
FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC
The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.
Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases
R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.
FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma
The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.
Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between…